Compare Abeona Therapeutics Inc (ABEO) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares Self-Driving EV and Tech — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while iShares Self-Driving EV and Tech trades at $36.18. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.
| ABEO | IDRV | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $45.48 |
52-Week Low | $4.17 | $31.81 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
IDRV trades at $38.51, up 2.01% today, but technical indicators signal a bearish trend with moving averages showing strong selling pressure. The ETF faces industry headwinds as rising fuel prices boost EV demand globally while US market adoption lags. Recent news highlights competitive threats from Chinese EV makers expanding internationally and regulatory uncertainty around US-China trade policies.
The ETF's outlook is challenged by sector volatility and geopolitical risks, though global EV adoption trends provide long-term growth potential. Key risks include tariff policy changes and slower-than-expected US EV adoption. Investors should monitor quarterly flows and sector performance for directional cues amid mixed technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →
